<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04000607</url>
  </required_header>
  <id_info>
    <org_study_id>2018-11</org_study_id>
    <nct_id>NCT04000607</nct_id>
  </id_info>
  <brief_title>Exploratory Study of the Edwards Transcatheter Atrial Shunt System (ALt FLOW CANADA)</brief_title>
  <official_title>Exploratory Study of the Edwards Transcatheter Atrial Shunt System (ALt FLOW CANADA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Exploratory study of the Edwards Transcatheter Atrial Shunt System is a multi-center,
      prospective, exploratory study to evaluate initial clinical safety, device functionality, and
      effectiveness of the Edwards Transcatheter Atrial Shunt System.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of major adverse cardiac, cerebrovascular, renal events (MACCRE) and re-intervention for study device related complications at 30 days.</measure>
    <time_frame>30 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>Day 0</time_frame>
    <description>Device is deployed as intended and the delivery system is successfully removed as intended at the time of the patient's exit from the implant procedure room.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>10 Days post-op</time_frame>
    <description>Device success with evidence of shunt patency and hospital discharge without the need for additional surgical or percutaneous intervention related to the study device including unacceptable Qp/Qs values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>30 Days</time_frame>
    <description>Procedural success without major adverse cardiac, cerebrovascular, and renal events (MACCRE) or re-intervention for study device related complications at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance/Effectiveness</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
    <description>Comparison vs baseline of Qp/Qs value at 3 &amp; 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance/Effectiveness</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
    <description>Improvement vs baseline of PCWP at 3 &amp; 6 months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Edwards Transcatheter Atrial Shunt System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Atrial Shunt</intervention_name>
    <description>Transcatheter treatment of symptomatic left heart failure patients</description>
    <arm_group_label>Edwards Transcatheter Atrial Shunt System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed and dated approved informed consent form prior to study related procedures

          2. Eighteen years of age or older

          3. Chronic symptomatic Heart Failure (HF) documented by the following:

               1. NYHA class II with a history of NYHA class III or greater; NYHA class III, OR
                  ambulatory NYHA class IV within last 12 months AND

               2. ≥ 1 HF hospital admission (with HF as the primary, or secondary diagnosis); OR
                  treatment with intravenous (IV) or intensification of oral diuresis for HF in a
                  healthcare facility (emergency department/acute care facility) within the 12
                  months prior to study entry

          4. In the judgment of the investigator, subject is on stable Guideline Directed Medical
             Therapy (GDMT) for heart failure and management of potential comorbidities according
             to current ACCF/AHA Guidelines and that is expected to be maintained without change
             for 3 months

          5. Elevated LA (or PCWP) pressure of &gt; 15 mmHg at rest or &gt; 25 mmHg during supine
             ergometer exercise stress test as measured at end-expiration; AND the LA (or PCWP)
             exceeds right atrial pressure (RAP) by &gt; 5 mmHg at rest or &gt; 10 mmHg during supine
             ergometer exercise stress test as measured at end-expiration

          6. Willing to attend study follow-up assessments for up to 3 years

        Exclusion Criteria:

          1. Severe heart failure defined as one or more of the below:

               1. ACC/AHA/ESC Stage D heart failure, non-ambulatory NYHA Class IV HF

               2. If BMI &lt; 30, Cardiac index &lt; 2.0 L/min/m2

               3. If BMI ≥ 30, Cardiac index &lt; 1.8 L/min/m2

               4. Inotropic infusion (continuous or intermittent) within the past 6 months

               5. Patient is on the cardiac transplant waiting list

               6. LVEF &lt; 20%

          2. Presence of significant valve disease defined by the site cardiologist as:

               1. Mitral valve regurgitation defined as grade &gt; 3+ MR or &gt; moderate MS

               2. Tricuspid valve regurgitation defined as grade &gt; 2+ TR

               3. Aortic valve disease defined as &gt; 2+ AR or &gt; moderate AS

          3. MI and/or any therapeutic invasive cardiac procedure within past 3 months; or current
             indication for coronary revascularization;

          4. Valve replacement or surgical annuloplasty within the past 12 months

          5. Cardiac Resynchronization Therapy initiated, stroke or transient ischemic attack (TIA)
             within the past 6 months

          6. Hemodynamic instability within 30 days of scheduled implant procedure

          7. Patient requiring surgery under general anesthesia for any reason within 30 days of
             scheduled implant procedure

          8. Clinically diagnosed hypertrophic obstructive cardiomyopathy, constrictive
             pericarditis or other infiltrative cardiomyopathy (eg, hemochromatosis, sarcoidosis)

          9. Has renal insufficiency as determined by creatinine (S-Cr) level &gt; 220 micrmol/L or
             estimated-GFR &lt;25ml/min/1.73 m2 by CKD-Epi equation; or currently requiring dialysis

         10. Significant hepatic impairment defined as 3× upper limit of normal of transaminases,
             total bilirubin, or alkaline phosphatase

         11. Right ventricular dysfunction, defined by the site cardiologist as:

               1. More than mild RV dysfunction as estimated by TTE; OR

               2. TAPSE &lt;1.4 cm; OR

               3. RV size ≥ LV size as estimated by TTE; OR

               4. Echocardiographic or clinical evidence of congestive hepatopathy;

         12. Evidence of pulmonary hypertension with PVR &gt;4 Wood units

         13. Performance of the 6 minute walk test with a distance &lt;50m OR &gt;400m

         14. Subject is contraindicated to receive either dual antiplatelet therapy or warfarin
             (analogue); or has a documented coagulopathy.

         15. Known hypersensitivity to anticoagulation therapy or contrast agent, which cannot be
             adequately medicated

         16. Known hypersensitivity to Nickel

         17. In the judgment of the investigator, life expectancy &lt;12 months for noncardiovascular
             reasons

         18. In the opinion of the investigator, the subject is not an appropriate candidate for
             the study

         19. Anatomy (including implantable devices) that is not compatible with the Edwards
             Transcatheter Atrial Shunt System

         20. Active endocarditis or infection within 3 months of scheduled implant procedure

         21. Currently participating (e.g. undergoing trial specific exams/treatment/ procedures)
             in an investigational drug or device study. Note: trials requiring extended follow-up
             for products that were investigational but have since become commercially available
             are not considered investigational trials.

         22. History of intravenous drug use in the last 12 months

         23. Positive serum pregnancy test in female subjects of child-bearing potential or nursing
             mothers or planning on becoming pregnant during the duration of the trial

         24. Patient is under guardianship

         25. Known pre-existing shunting, determined to be clinically significant by the
             investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Melissa Arteaga</last_name>
    <phone>949-250-2002</phone>
    <email>Melissa_Arteaga@edwards.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana Gonzalez</last_name>
    <phone>949-250-4419</phone>
    <email>Ana_L_Gonzalez@edwards.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naomi Uchida</last_name>
      <phone>604-875-4521</phone>
      <email>naomi.uchida@ubc.ca</email>
    </contact>
    <investigator>
      <last_name>Jacqueline Saw, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Feagan</last_name>
      <phone>613-696-7000</phone>
      <phone_ext>12678</phone_ext>
      <email>hfeagan@ottawaheart.ca</email>
    </contact>
    <investigator>
      <last_name>Benjamin Hibbert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 24, 2019</study_first_submitted>
  <study_first_submitted_qc>June 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

